← Back to Search

Radiation

Radiation Therapy for Breast Cancer (DCIS Trial)

N/A
Waitlist Available
Research Sponsored by Trans Tasman Radiation Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women ≥ 18 years.
Histologically proven DCIS of the breast without an invasive component.
Must not have
ECOG performance status ≥ 3.
Women who are pregnant or lactating.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at baseline, last week of rt, 3, 6, and 12 months post rt and then yearly until year 10.
Awards & highlights

Summary

This trial is testing whether adding a tumour bed boost after breast conserving surgery (BCS) in women with non-low risk ductal carcinoma in situ (DCIS) reduces the risk of local recurrence. There are two fractionation arms in this trial: a shorter fractionation arm and a standard fractionation arm. The overall objectives of the trial are to improve the outcome of women with non-low risk DCIS treated with BCS and to individualize treatment selection for women with DCIS to achieve long term disease control with minimal toxicity.

Who is the study for?
This trial is for women over 18 with non-low risk DCIS of the breast, treated by breast conserving surgery. They must be clinically node-negative, able to start radiation within 12 weeks post-surgery, and have a life expectancy over 5 years. Exclusions include pregnant or lactating women, those with lymph node tumor cells, bilateral DCIS, previous contralateral breast cancer or serious diseases like scleroderma.
What is being tested?
The study tests if adding a boost after whole breast radiation (WBRT) reduces recurrence in high-risk DCIS patients and compares shorter vs standard WBRT schedules. It also aims to find molecular signatures predicting invasive recurrence to personalize treatment.
What are the potential side effects?
While not explicitly listed here, potential side effects generally associated with radiation therapy may include skin irritation at the treatment site, fatigue, mild swelling in the treated area and changes in breast texture.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 18 or older.
Select...
My breast cancer is non-invasive and confirmed by tissue analysis.
Select...
My cancer has not spread to my lymph nodes.
Select...
I can take care of myself and perform daily activities.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have significant difficulty in performing daily activities.
Select...
I am not pregnant or breastfeeding.
Select...
I have cancer in both breasts at the same time.
Select...
My breast cancer has come back in the same area.
Select...
My cancer has spread to my lymph nodes.
Select...
I have DCIS in both breasts.
Select...
I have had cancer in my other breast before.
Select...
I have a serious illness like heart, lung, or kidney disease that prevents surgery or radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at baseline, last week of rt, 6, 12, 24, 60 & 120 months post rt.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at baseline, last week of rt, 6, 12, 24, 60 & 120 months post rt. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to local recurrence, measured from the date of randomization to the date of first evidence of local recurrence.
Secondary study objectives
Cosmetic Outcome
Overall survival
Quality of Life change
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Arm 4 (Shorter WB fractionation + Boost)Experimental Treatment1 Intervention
Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
Group II: Arm 2 (Shorter WB Fractionation)Experimental Treatment1 Intervention
Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
Group III: Arm 1 (Standard WB Fractionation)Active Control1 Intervention
Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
Group IV: Arm 3 (Standard WB fractionation+Boost)Active Control1 Intervention
Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)

Find a Location

Who is running the clinical trial?

Trans Tasman Radiation Oncology GroupLead Sponsor
48 Previous Clinical Trials
14,981 Total Patients Enrolled
NCIC Clinical Trials GroupNETWORK
189 Previous Clinical Trials
143,233 Total Patients Enrolled
Cancer Trials IrelandNETWORK
84 Previous Clinical Trials
23,957 Total Patients Enrolled

Media Library

Shorter WB fractionation (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT00470236 — N/A
Breast Carcinoma Research Study Groups: Arm 1 (Standard WB Fractionation), Arm 4 (Shorter WB fractionation + Boost), Arm 3 (Standard WB fractionation+Boost), Arm 2 (Shorter WB Fractionation)
Breast Carcinoma Clinical Trial 2023: Shorter WB fractionation Highlights & Side Effects. Trial Name: NCT00470236 — N/A
Shorter WB fractionation (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00470236 — N/A
~88 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top